Xvivo Perfusion: NOVEL study is fully recruited

Research Note

2017-07-06

14:57

With a total of 220 (110+110) patients included, the recruitment of the NOVEL study has now been completed. The trial studies the use of the XPS and STEEN Solution during normothermic (warm) lung perfusion and will be the basis for the company’s PMA (Pre-Market Approval) application. The current HDE (Humanitarian Device Exemption) approval, along with the enrollment to the NOVEL study, are believed to have held back sales related to warm perfusion.

AN

Arvid Necander

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.